x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Few & Far Between: How Biotech Gets Built

Welcome to Few & Far Between! Chris O"Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

science life sciences

All Episodes

00:51:43

Episode 36: Zak Kohane, Department of Biomedical...

Few & Far Between: How Biotech Gets Built ·

2023/12/05

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benefits. And we need to engage the public in defining what those [AI] policies are." Isaac [Zak] Kohane,Professor and Chair, Department of Biomedical Informatics, Harvard Medical School Buckle up for the latest Few & Far Between podcast! We're taking a tour of the current state of AI in healthcare and clinical research. Join host Chris O'Brien and

en

00:51:43

Episode 36: Zak Kohane, Department of Biomedical...

Few & Far Between: How Biotech Gets Built ·

2023/12/05

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benefits. And we need to engage the public in defining what those [AI] policies are." Isaac [Zak] Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School Buckle up for the latest Few & Far Between podcast! We're taking a tour of the current state of AI in healthcare and clinical research. Join host

en

00:44:55

Episode 35: Charlene Son Rigby, CEO at Global Genes

Few & Far Between: How Biotech Gets Built ·

2023/11/14

"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot of recreation of the wheel when advocacy groups have not necessarily ever run a research study.And so I kept thinking about what opportunities do we have across rare disease to really elevate and accelerate all of this work around data collection." - Charlene Son Rigby, CEO at Global Genes Welcome to Biorasi's Few & Far Between podcast! Join host

en

00:44:55

Episode 35: Charlene Son Rigby, CEO at Global Genes

Few & Far Between: How Biotech Gets Built ·

2023/11/14

"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot of recreation of the wheel when advocacy groups have not necessarily ever run a research study. And so I kept thinking about what opportunities do we have across rare disease to really elevate and accelerate all of this work around data collection." - Charlene Son Rigby, CEO at Global Genes Welcome to Biorasi's Few & Far

en

00:44:45

Episode 34: Dan Mandell, CEO at GRO Biosciences

Few & Far Between: How Biotech Gets Built ·

2023/10/10

"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy that we used actually drew from all of my past experience in computational protein design and combined it with these incredible new organisms." - Dan Mandell, CEO at GRO Biosciences Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Dan Mandell, CEO at GRO Biosciences, as they discuss the latest

en

00:44:45

Episode 34: Dan Mandell, CEO at GRO Biosciences

Few & Far Between: How Biotech Gets Built ·

2023/10/10

"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy that we used actually drew from all of my past experience in computational protein design and combined it with these incredible new organisms." - Dan Mandell, CEO at GRO Biosciences Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Dan Mandell, CEO at GRO Biosciences, as they discuss the latest breakthroughs in protein

en

00:26:33

Episode 33: Diana Sims-Silbermann, Clinician and...

Few & Far Between: How Biotech Gets Built ·

2023/09/20

en

00:26:33

Episode 33: Diana Sims-Silbermann, Clinician and...

Few & Far Between: How Biotech Gets Built ·

2023/09/20

en

00:37:05

Episode 32: Stephanie Wisner, Author, Co-Founder at...

Few & Far Between: How Biotech Gets Built ·

2023/08/17

"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner,Author, Co-Founder at Centivax Biorasi is excited to welcome Stephanie Wisner to the Few & Far Between podcast. Stephanie is the author of "Building Backwards to Biotech: The Power of Entrepreneurship to Drive Cutting-Edge Science to Market." Join host Chris O'Brien as we explore the multitude of opportunities and pitfalls in today's biotech industry. Stephanie's book is availabe on

en

00:37:05

Episode 32: Stephanie Wisner, Author, Co-Founder at...

Few & Far Between: How Biotech Gets Built ·

2023/08/17

"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax Biorasi is excited to welcome Stephanie Wisner to the Few & Far Between podcast. Stephanie is the author of "Building Backwards to Biotech: The Power of Entrepreneurship to Drive Cutting-Edge Science to Market." Join host Chris O'Brien as we explore the multitude of opportunities and pitfalls in today's biotech

en

00:44:32

Episode 31: Pam Cusick, SVP, Rare Patient Voice

Few & Far Between: How Biotech Gets Built ·

2023/06/20

"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts in their condition and they know more about the everyday kind of what they go through than their doctor even would because they're not with them 24/7." - Pam Cusick, SVP, Rare Patient Voice Biorasi's Marc Gas welcomes Pam Cusick, SVP at Rare Patient Voice, to the Few & Far Between podcast for an episode focusing on the power of rare patient input across the

en

00:44:32

Episode 31: Pam Cusick, SVP, Rare Patient Voice

Few & Far Between: How Biotech Gets Built ·

2023/06/20

"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts in their condition and they know more about the everyday kind of what they go through than their doctor even would because they're not with them 24/7." - Pam Cusick, SVP, Rare Patient Voice Biorasi's Marc Gas welcomes Pam Cusick, SVP at Rare Patient Voice, to the Few & Far Between podcast for an episode focusing on the power of rare patient

en

00:35:12

Episode 30, Part Two: Dr. Francisco Harrison, CEO and...

Few & Far Between: How Biotech Gets Built ·

2023/05/23

"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that indicate that there may be hope for that patient, we should do something to hear the voice of that patient and learn." -Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH Welcome back to part two of our conversation with Dr. Francisco Harrison. Join us in this Few & Far Between episode as we dive deeper to discuss new opportunities, new responsibilities,

en

00:35:12

Episode 30, Part Two: Dr. Francisco Harrison, CEO and...

Few & Far Between: How Biotech Gets Built ·

2023/05/23

"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that indicate that there may be hope for that patient, we should do something to hear the voice of that patient and learn." - Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH Welcome back to part two of our conversation with Dr. Francisco Harrison. Join us in this Few & Far Between episode as we dive deeper to discuss new opportunities,

en

00:45:07

Episode 30, Part One: Dr. Francisco Harrison, CEO and...

Few & Far Between: How Biotech Gets Built ·

2023/05/03

"I love clinical research. I will spend my life in clinical research."Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH Biorasi welcomes Dr. Francisco Harrison to the Few and Far Between podcast for a special two-part episode. In part one, we track Dr. Harrison's origin story - from medical school to his first forays into clinical research.

en

00:45:07

Episode 30, Part One: Dr. Francisco Harrison, CEO and...

Few & Far Between: How Biotech Gets Built ·

2023/05/03

"I love clinical research. I will spend my life in clinical research." Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH Biorasi welcomes Dr. Francisco Harrison to the Few and Far Between podcast for a special two-part episode. In part one, we track Dr. Harrison's origin story - from medical school to his first forays into clinical research.

en

00:46:50

Episode 29: Mika Newton, CEO at XCures

Few & Far Between: How Biotech Gets Built ·

2023/03/21

"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the future and providing them and their physicians with decision support and alternative thinking about ways to treat their cancer." Mika Newton, CEO at xCures Biorasi welcomes Mika Newton to the Few & Far Between podcast to examine how the connection between AI and oncology leads to a more patient-centric world.

en

00:46:50

Episode 29: Mika Newton, CEO at XCures

Few & Far Between: How Biotech Gets Built ·

2023/03/21

"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the future and providing them and their physicians with decision support and alternative thinking about ways to treat their cancer." Mika Newton, CEO at xCures Biorasi welcomes Mika Newton to the Few & Far Between podcast to examine how the connection between AI and oncology leads to a more patient-centric world.

en

00:30:48

Episode 28: Dr. Alok Tayi, Founder and CEO of VibeBio

Few & Far Between: How Biotech Gets Built ·

2023/02/23

“I think one of the key insights and observations you make when you have a child who's sick and you spend time with other families who have sick kids is that we all have a tremendous amount of hope that a potential treatment will come to the forefront for our child.” – Dr. Alok Tayi, Founder and CEO of Vibe Bio Biorasi welcomes Dr. Alok Tayi to the Few & Far Between podcast to explore the power and determination that patients have when it comes to finding a treatment for

en

00:30:48

Episode 28: Dr. Alok Tayi, Founder and CEO of VibeBio

Few & Far Between: How Biotech Gets Built ·

2023/02/23

“I think one of the key insights and observations you make when you have a child who's sick and you spend time with other families who have sick kids is that we all have a tremendous amount of hope that a potential treatment will come to the forefront for our child.” – Dr. Alok Tayi, Founder and CEO of Vibe Bio Biorasi welcomes Dr. Alok Tayi to the Few & Far Between podcast to explore the power and determination that patients have when it comes to finding a treatment for rare

en

121 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter